Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 6.18B -7.1% |
| Revenue (ttm) | 239.92M +53.5% |
| Net Income | -210.22M |
| EPS | -3.12 |
| Shares Out | 68.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 537,962 |
| Open | 91.05 |
| Previous Close | 90.78 |
| Day's Range | 89.49 - 91.42 |
| 52-Week Range | 74.50 - 122.20 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | 138.88 (+54.62%) |
| Est. Earnings | Nov 3, 2026 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for RYTM stock is "Buy." The 12-month stock price target is $138.88, which is an increase of 54.62% from the latest price.
News
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra...
Rhythm Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing three strategic pillars—genetic obesity, HO, and Prader-Willi—with IMCIVREE and next-gen MC4R agonists. Early HO launch shows broad physician interest, with payer adoption strong and international expansion underway. Key clinical and regulatory milestones are expected by year-end.
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated...
Rhythm Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
The business is advancing three rare disease pillars, with a strong HO launch showing broad prescriber engagement and favorable payer trends. Prader-Willi development is progressing with positive phase II data and strategic plans for pivotal trials. Financially, the company is well-resourced to invest in growth and R&D.
Rhythm Pharmaceuticals Slides: Corporate presentation
Rhythm Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference
IMCIVREE continues to expand globally, with strong AHO launch momentum and broad physician adoption. Pipeline advances include upcoming phase III trials for oral and injectable MC4R agonists and plans for a pivotal PWS study. Cash reserves support operations for two years.
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals said on Tuesday its experimental weekly injectable drug helped reduce body weight in patients with a rare form of obesity caused by damage to the brain, according to prelimina...
Rhythm Pharmaceuticals Earnings Call Transcript: Q2 2026
IMCIVREE's U.S. launch for acquired hypothalamic obesity drove strong Q2 sales growth, with robust early demand, broad prescriber engagement, and positive payer response. International expansion and next-generation MC4R agonist development are progressing, supporting long-term growth.
Rhythm Pharmaceuticals Earnings release: Q2 2026
Rhythm Pharmaceuticals released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Rhythm Pharmaceuticals Slides: Q2 2026
Rhythm Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Rhythm Pharmaceuticals Quarterly report: Q2 2026
Rhythm Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 4, 2026.
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
-- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 202...
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon --
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Study result
Interim phase II results in severe Prader-Willi syndrome show setmelanotide led to consistent reductions in BMI, fat mass, hyperphagia, and anxiety, with notable behavioral and quality of life improvements. The drug was well-tolerated, and all patients remained in the trial at six months.
Rhythm Pharmaceuticals Slides: Study result
Rhythm Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 13, 2026.
Rhythm Pharmaceuticals Press release: Study result
Rhythm Pharmaceuticals issued a press release on June 13, 2026, disclosing material business information to investors.
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in ...
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Six-month data for Praloretel and updated RM-718 results will be presented at ENDO, while IMCIVREE's HO launch targets a 10,000-patient U.S. market with strong physician interest and high anticipated adherence. The pipeline includes both oral and injectable options, with a focus on rare diseases and a solid cash position for ongoing development.